Pfizer ends Covid-19 trial with 95pct efficacy, to seek emergency-use authorisation

Pfizer Inc said final results from the late-stage trial of its Covid-19 vaccine show it was 95 percent effective, adding that it had the required two-months of safety data and would apply for emergency US authorisation within days.

The drugmaker said the efficacy of the vaccine developed with German partner BioNTech SE was consistent across age and ethnicity demographics, and that there were no major side effects, a sign that the immunisation could be employed broadly around the world...